Table 1.
Baseline characteristics of patients with COVID-19.
| Normal Cytokine Levels | Increased Cytokine Levels | Total | p Value | ||
|---|---|---|---|---|---|
| Number | 61 | 75 | 136 | p > 0.05 | |
| Age (year) (range) | 58 (21–59) | 55 (23–64) | 56 (21–64) | p > 0.05 | |
| Gender (male/female) | 43/18 | 45/30 | 86/50 | p > 0.05 | |
| Abnormal coagulation tests: n (%) | D-dimer | 5 (31.2%) | 11 (68.8%) | 16 | NA |
| PT | 6 (40%) | 9 (60%) | 15 | ||
| APTT | 6 (46.2%) | 7 (53.8%) | 13 | ||
| FDP | 6 (40%) | 9 (60%) | 15 | ||
| Fibrinogen | 2 (25%) | 6 (75%) | 8 | ||
| FXII | 0 | 2 (100%) | 2 | ||
| DVT/PE | 5 | 26 | 31 | p < 0.001 | |
| Underlying disorders | Diabetes | 3 | 2 | 22 | NA |
| Renal failure | 0 | 1 | |||
| Hepatic failure | 0 | 1 | |||
| Cancer | 2 | 1 | |||
| Hypothyroidism | 1 | 2 | |||
| Cardiovascular disorders | 6 | 3 | |||
| Death | 1 | 6 | 7 | p < 0.001 | |
DVT: Deep vein thrombosis, PE: Pulmonary embolism, PT: Prothrombin time, APTT; Activated partial thromboplastin time, Fib: Fibrinogen, FDP; Fibrin(ogen) degradation products, FXII: Factor XII.